Literature DB >> 20595732

[What are we learning from the new data on cancer incidence in North Africa].

Irene Sobrato1, Paola Busso, Roberto Zanetti.   

Abstract

Over a period of a few years, Cancer registries in North Africa (Morocco, Algeria, Tunisia, Libya, Egypt) increased in number from one to seven. Currently they serve 9.7% of the total regional population. The pattern of risk presented by their data (which appear to be good enough, according to the available indicators) is unique. The total cancer burden in different North Africa countries is between one fourth and one half (on average one third) of the corresponding risk in Europe. The overall rate, age standardized on world population, ranges in men from 94.0/100,000 in Sètif, Algeria, to 162.9/100,000 in Garbiah, Egypt. Similar is the range of the risk between countries in women (from 84.7 and 164.0/100,000). The case mixing and the level of the site specific rates are quite homogeneous between the considered countries. The most frequent cancers are those observed in Europe (lung, breast, colon, prostate). This pattern completely differs from that of black Africa countries, where infection-related cancers predominate. The clinically well known excess risk for nasopharyngeal carcinoma in Maghrebi countries is confirmed and quantified by the presented data (with rates as high as 5.4/100,000 in men and 1.9/100,000 in women, ten times higher than in Europe).

Entities:  

Mesh:

Year:  2010        PMID: 20595732

Source DB:  PubMed          Journal:  Epidemiol Prev        ISSN: 1120-9763            Impact factor:   1.901


  2 in total

1.  Indications and outcome of colonoscopy in the middle of Nile delta of Egypt.

Authors:  Hasan Elbatea; Mohamed Enaba; Galal Elkassas; Ferial El-Kalla; Asem Ahmed Elfert
Journal:  Dig Dis Sci       Date:  2011-01-08       Impact factor: 3.199

2.  Cancers in Eastern Libya: first results from Benghazi Medical Center.

Authors:  Zuhir Bodalal; Raouf Azzuz; Riyad Bendardaf
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.